259 related articles for article (PubMed ID: 31122273)
1. Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.
Shibeshi W; Sheth AN; Admasu A; Berha AB; Negash Z; Yimer G
BMC Pharmacol Toxicol; 2019 May; 20(1):31. PubMed ID: 31122273
[TBL] [Abstract][Full Text] [Related]
2. The safety and tolerability of the second-line injectable antituberculosis drugs in children.
Garcia-Prats AJ; Schaaf HS; Hesseling AC
Expert Opin Drug Saf; 2016 Nov; 15(11):1491-1500. PubMed ID: 27548570
[TBL] [Abstract][Full Text] [Related]
3. Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis.
Arnold A; Cooke GS; Kon OM; Dedicoat M; Lipman M; Loyse A; Chis Ster I; Harrison TS
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696239
[TBL] [Abstract][Full Text] [Related]
4. Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia.
Buziashvili M; Mirtskhulava V; Kipiani M; Blumberg HM; Baliashvili D; Magee MJ; Furin JJ; Tukvadze N; Kempker RR
Int J Tuberc Lung Dis; 2019 Sep; 23(9):1005-1011. PubMed ID: 31615608
[TBL] [Abstract][Full Text] [Related]
5. Risk of Nephrotoxicity in Patients With Drug-Resistant Tuberculosis Treated With Kanamycin/Capreomycin With or Without Concomitant Use of Tenofovir-Containing Antiretroviral Therapy.
Perumal R; Abdelghani N; Naidu N; Yende-Zuma N; Dawood H; Naidoo K; Singh N; Padayatchi N
J Acquir Immune Defic Syndr; 2018 Aug; 78(5):536-542. PubMed ID: 29683992
[TBL] [Abstract][Full Text] [Related]
6. Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort.
Sagwa EL; Ruswa N; Mavhunga F; Rennie T; Leufkens HG; Mantel-Teeuwisse AK
BMC Pharmacol Toxicol; 2015 Dec; 16():36. PubMed ID: 26654443
[TBL] [Abstract][Full Text] [Related]
7. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.
Sturdy A; Goodman A; José RJ; Loyse A; O'Donoghue M; Kon OM; Dedicoat MJ; Harrison TS; John L; Lipman M; Cooke GS
J Antimicrob Chemother; 2011 Aug; 66(8):1815-20. PubMed ID: 21642291
[TBL] [Abstract][Full Text] [Related]
8. Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.
Sarin R; Behera D; Khanna A; Singh V; Narang P; Deepak TS
Indian J Tuberc; 2019 Apr; 66(2):279-287. PubMed ID: 31151497
[TBL] [Abstract][Full Text] [Related]
9. [Kanamycin-induced ototoxicity during treatment of multidrug-resistant tuberculosis].
Poka-Mayap V; Balkissou Adamou D; Pefura-Yone EW; Kuaban C
Rev Mal Respir; 2020 May; 37(5):369-375. PubMed ID: 32278508
[TBL] [Abstract][Full Text] [Related]
10. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
11. Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa.
Pietersen E; Anderson K; Cox H; Dheda K; Bian A; Shepherd BE; Sterling TR; Warren RM; van der Heijden YF
PLoS One; 2023; 18(2):e0281097. PubMed ID: 36780443
[TBL] [Abstract][Full Text] [Related]
12. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis.
de Jager P; van Altena R
Int J Tuberc Lung Dis; 2002 Jul; 6(7):622-7. PubMed ID: 12102302
[TBL] [Abstract][Full Text] [Related]
13. Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.
Wrohan I; Redwood L; Ho J; Velen K; Fox GJ
Int J Tuberc Lung Dis; 2021 Jan; 25(1):23-30. PubMed ID: 33384041
[No Abstract] [Full Text] [Related]
14. Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.
Sagwa EL; Souverein PC; Ribeiro I; Leufkens HG; Mantel-Teeuwisse AK
Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):1-8. PubMed ID: 27868278
[TBL] [Abstract][Full Text] [Related]
15. Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.
Muñoz-Torrico M; Caminero-Luna J; Migliori GB; D'Ambrosio L; Carrillo-Alduenda JL; Villareal-Velarde H; Torres-Cruz A; Flores-Vergara H; Martínez-Mendoza D; García-Sancho C; Centis R; Salazar-Lezama MÁ; Pérez-Padilla R
Arch Bronconeumol; 2017 May; 53(5):245-250. PubMed ID: 28089216
[TBL] [Abstract][Full Text] [Related]
16. Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.
Ramma L; Nhokwara PT; Rogers C
S Afr J Commun Disord; 2019 Jan; 66(1):e1-e6. PubMed ID: 30843411
[TBL] [Abstract][Full Text] [Related]
17. Intensive phase treatment outcome and associated factors among patients treated for multi drug resistant tuberculosis in Ethiopia: a retrospective cohort study.
Molie T; Teklemariam Z; Klinkenberg E; Dessie Y; Kumsa A; Mohammed H; Debebe A; Assefa D; Habte A; Bedru A; Fiseha D; Seyoum B
BMC Infect Dis; 2019 Sep; 19(1):818. PubMed ID: 31533644
[TBL] [Abstract][Full Text] [Related]
18. Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia.
Mesfin EA; Beyene D; Tesfaye A; Admasu A; Addise D; Amare M; Dagne B; Yaregal Z; Tesfaye E; Tessema B
PLoS One; 2018; 13(6):e0197737. PubMed ID: 29864118
[TBL] [Abstract][Full Text] [Related]
19. Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam.
Ngoc NB; Vu Dinh H; Thuy NT; Quang DV; Huyen CTT; Hoa NM; Anh NH; Dat PT; Hoa NB; Tiemersma E; Nhung NV
PLoS One; 2021; 16(9):e0255357. PubMed ID: 34492031
[TBL] [Abstract][Full Text] [Related]
20. [Investigation of extensive drug resistance in multidrug resistance tuberculosis isolates].
Bektöre B; Haznedaroğlu T; Baylan O; Ozyurt M; Ozkütük N; Satana D; Cavuşoğlu C; Seber E
Mikrobiyol Bul; 2013 Jan; 47(1):59-70. PubMed ID: 23390903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
